Vapotherm (VAPO) Q2 2024 earnings summary

Executive summary

• Net revenue for Q2 2024 was $16.9M, up 5.3% year-over-year, driven by strong U.S. disposables growth, while capital equipment revenue declined.

• U.S. disposables revenue rose 25.9% year-over-year, with global disposables up 13.9% due to increased adoption of HVT 2.0.

• Net loss for Q2 2024 was $14.3M ($2.22/share), a slight improvement from $14.8M ($2.34/share) in Q2 2023; six-month net loss was $29.1M, down from $32.9M year-over-year.

• Adjusted EBITDA loss narrowed to $2.9M from $6.4M year-over-year, reflecting cost control initiatives.

• A definitive merger agreement was signed in June 2024; if completed, shareholders will receive $2.18 per share in cash.

Financial highlights

• Q2 2024 net revenue: $16.9M (+5.3% YoY); six months: $36.0M (+6.7% YoY).

• Gross margin improved to 49.1% in Q2 2024 from 42.8% in Q2 2023, driven by operational efficiency in Mexico.

• Net loss: $14.3M for Q2 2024 ($2.22/share); $29.1M for six months ($4.52/share).

• Operating cash outflow for six months: $9.8M, improved from $17.4M in prior year.

• Unrestricted cash and cash equivalents at June 30, 2024: $2.9M; negative working capital of $109.9M.

Outlook and guidance

• Management expects continued net losses for several years and will require additional funding.

• FDA clearance for Access365 home ventilation solution anticipated in 2025.

• Merger expected to close in the second half of 2024, subject to customary conditions.